Filip Janku, MD, PhD, discusses the results form a phase 1 study (NCT02571036) of ripretinib (Qinlock), a broad-spectrum KIT and PDGFRA inhibitor, in patients with 

The data that came out of this study demonstrated a higher efficacy than what has previously been reported, according to Janku. When evaluating confirmed responses with stringent criteria, 1 complete response and 5 partial responses were observed, which translates to an overall response rate of approximately 23% in the intent-to-treat population of 26 patients, Janku explains.

There were additionally 2 unconfirmed responses, and with these included, the ORR would be 31%, Janku adds. Even more importantly, the patient responses to ripretinib proved to be durable, with a median duration of response over 9.0 months, and a progression-free survival of 7.3 months, which is the most positive data ever reported for this patient population, Janku concludes. 

Videos

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. This study was presented at the 2014 ASCO Annual Meeting.

While BRAF mutation status changes over time, constantly biopsying patients is not feasible for a number of reasons. There remains a need for an alternative source of mutational analysis that can work over time.

The purpose of this study was to monitor the amount of BRAF mutation in a patient’s plasma and use it as a surrogate for response to therapy.

Filip Janku, MD, PhD, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.

Filip Janku, MD, PhD

Articles

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Dr. Janku on Longitudinal Monitoring of BRAF V600E Mutation in Urinary Cell-Free DNA